Taysha Gene Therapies (TSHA) – Analysts’ Weekly Ratings Changes

Several analysts have recently updated their ratings and price targets for Taysha Gene Therapies (NASDAQ: TSHA):

• 3/27/2026 – Taysha Gene Therapies had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 3/25/2026 – Taysha Gene Therapies was upgraded by Truist Financial Corporation to “strong-buy”.
• 3/21/2026 – Taysha Gene Therapies was upgraded by Wall Street Zen from “sell” to “hold”.
• 3/19/2026 – Taysha Gene Therapies had its price target raised by Needham & Company LLC from $10.00 to $12.00. They now have a “buy” rating on the stock.
• 3/19/2026 – Taysha Gene Therapies had its “buy” rating reaffirmed by Chardan Capital. They now have a $12.00 price target on the stock.
• 3/3/2026 – Taysha Gene Therapies had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $10.00 price target on the stock.

Insider Buying and Selling at Taysha Gene Therapies

In other news, insider Sukumar Nagendran sold 200,000 shares of the firm’s stock in a transaction that occurred on Monday, January 12th. The shares were sold at an average price of $4.71, for a total transaction of $942,000.00. Following the sale, the insider owned 1,006,439 shares of the company’s stock, valued at $4,740,327.69. This trade represents a 16.58% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Kamran Alam sold 78,968 shares of Taysha Gene Therapies stock in a transaction that occurred on Friday, January 23rd. The shares were sold at an average price of $4.75, for a total transaction of $375,098.00. Following the transaction, the chief financial officer directly owned 1,467,635 shares of the company’s stock, valued at approximately $6,971,266.25. This trade represents a 5.11% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 598,623 shares of company stock worth $2,822,188. Insiders own 3.78% of the company’s stock.

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.